CRDF Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 19.46%, SMA50 -15.66%, SMA200 -24.66%). The stock’s 14-day RSI is 52.9 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -56.97% below its high and over 32.43% above its low. Average 10-day trading volume of 1.06 million shares is below the 3-month average of 1.25 million, indicating normal recent market interest.

The stock is currently mid-range between its 52-week high and low $1.48 and $4.56. With a market capitalization of about $130.68 million, Cardiff Oncology, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.34). Key stats such as the average daily volume over the past year has been around 1.28 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Cardiff Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mani Mohindru, the company employs approximately 32 people and listed since July 27, 2004. Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California.

Cardiff Oncology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.06. This means the shares are trading below this model’s fair value.

Cardiff Oncology, Inc. generated EPS of -$0.69 over the past year. Five-year average earnings growth is 8.71%. Wall Street analysts project EPS growth of -17.0% annually over the next five years. The latest quarter delivered EPS of -$0.17. The next quarter is forecast at -$0.15. Next year's EPS is expected at -$21.27. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $19.00 to $3.50. The high target offers 879.38% upside. The low target suggests 80.41% downside. The mean target is $10.50. This offers 441.24% upside. Cardiff Oncology, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -15.0%. The prior quarter beat by 10.53%. Over the last six quarters, Apple has recorded several small beats. These include 4.0% in August 08, 2024.

Cardiff Oncology, Inc. has 66.53 million shares outstanding. The public float is 64.90 million shares, elevated short interest at 24.24% of float. This equals 15.70 million shares. The short ratio is 5.43 days. Institutional investors hold 42.24% of the float. Insiders own 6.05%. Hunter Robert Merrill holds 4.00 million shares, BRIDGER MANAGEMENT, LLC has 2.97 million shares and PACE GARY W has 1.33 million shares.

Cardiff Oncology, Inc. trades at a P/E ratio of -2.83, slightly below the S&P 500 average, with a price-to-sales ratio of 220.6 and a price-to-book ratio of 2.86 suggesting the stock is closer to book value. The P/FCF stands at -3.45, also below market averages.

Cardiff Oncology, Inc. (NASDAQ:CRDF) shares are flat 0.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cardiff Oncology, Inc. trading at a premium to the broader market with a P/E of -2.83. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $13.93, suggesting 618.04% upside. Our AI forecast model points to short-term weakness (-25.77% over two weeks), a medium-term rise (43.3% over three months), and a longer-term gain (51.55% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cardiff Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -25.77%, with price expected at $1.44 by March 13, 2026, within a range of $1.00 to $1.86 3-Month Outlook: Projected rise of 43.3%, reaching $2.78 by May 28, 2026, with a range of $2.51 to $2.98. 1-Year Outlook: Projected gain of 51.55%, with price at $2.94 by February 26, 2027, within a range of $0.00 to $1.51.